Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel.
AR copy number
AR-V7
CTC
Cabazitaxel
mCRPC
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
31 01 2022
31 01 2022
Historique:
received:
06
10
2021
accepted:
07
01
2022
entrez:
1
2
2022
pubmed:
2
2
2022
medline:
24
3
2022
Statut:
epublish
Résumé
Cabazitaxel improves overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients progressing after docetaxel. In this prospective study, we evaluated the prognostic role of CTC gene expression on cabazitaxel-treated patients and its association with plasma androgen receptor (AR) copy number (CN). Patients receiving cabazitaxel 20 or 25 mg/sqm for mCRPC were enrolled. Digital PCR was performed to assess plasma AR CN status. CTC enrichment was assessed using the AdnaTest EMT-2/StemCell kit. CTC expression analyses were performed for 17 genes. Data are expressed as hazard ratio (HR) or odds ratio (OR) and 95% CI. Seventy-four patients were fully evaluable. CTC expression of AR-V7 (HR=2.52, 1.24-5.12, p=0.011), AKR1C3 (HR=2.01, 1.06-3.81, p=0.031), AR (HR=2.70, 1.46-5.01, p=0.002), EPCAM (HR=3.75, 2.10-6.71, p< 0.0001), PSMA (HR=2.09, 1.19-3.66, p=0.01), MDK (HR=3.35, 1.83-6.13, p< 0.0001), and HPRT1 (HR=2.46, 1.44-4.18, p=0.0009) was significantly associated with OS. ALDH1 (OR=5.50, 0.97-31.22, p=0.05), AR (OR=8.71, 2.32-32.25, p=0.001), EPCAM (OR=7.26, 1.47-35.73, p=0.015), PSMA (OR=3.86, 1.10-13.50, p=0.035), MDK (OR=6.84, 1.87-24.98, p=0.004), and HPRT1 (OR=7.41, 1.82-30.19, p=0.005) expression was associated with early PD. AR CN status was significantly correlated with AR-V7 (p=0.05), EPCAM (p=0.02), and MDK (p=0.002) expression. In multivariable model, EPCAM and HPRT1 CTC expression, plasma AR CN gain, ECOG PS=2, and liver metastases and PSA were independently associated with poorer OS. In patients treated with cabazitaxel 20 mg/sqm, median OS was shorter in AR-V7 positive than negative patients (6.6 versus 14 months, HR=3.46, 1.47-8.17], p=0.004). Baseline CTC biomarkers may be prognosticators for cabazitaxel-treated mCRPC patients. Cabazitaxel at lower (20 mg/sqm) dose was associated with poorer outcomes in AR-V7 positive patients compared to AR-V7 negative patients in a post hoc subgroup analysis. Clinicaltrials.gov NCT03381326 . Retrospectively registered on 18 December 2017.
Sections du résumé
BACKGROUND
Cabazitaxel improves overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients progressing after docetaxel. In this prospective study, we evaluated the prognostic role of CTC gene expression on cabazitaxel-treated patients and its association with plasma androgen receptor (AR) copy number (CN).
METHODS
Patients receiving cabazitaxel 20 or 25 mg/sqm for mCRPC were enrolled. Digital PCR was performed to assess plasma AR CN status. CTC enrichment was assessed using the AdnaTest EMT-2/StemCell kit. CTC expression analyses were performed for 17 genes. Data are expressed as hazard ratio (HR) or odds ratio (OR) and 95% CI.
RESULTS
Seventy-four patients were fully evaluable. CTC expression of AR-V7 (HR=2.52, 1.24-5.12, p=0.011), AKR1C3 (HR=2.01, 1.06-3.81, p=0.031), AR (HR=2.70, 1.46-5.01, p=0.002), EPCAM (HR=3.75, 2.10-6.71, p< 0.0001), PSMA (HR=2.09, 1.19-3.66, p=0.01), MDK (HR=3.35, 1.83-6.13, p< 0.0001), and HPRT1 (HR=2.46, 1.44-4.18, p=0.0009) was significantly associated with OS. ALDH1 (OR=5.50, 0.97-31.22, p=0.05), AR (OR=8.71, 2.32-32.25, p=0.001), EPCAM (OR=7.26, 1.47-35.73, p=0.015), PSMA (OR=3.86, 1.10-13.50, p=0.035), MDK (OR=6.84, 1.87-24.98, p=0.004), and HPRT1 (OR=7.41, 1.82-30.19, p=0.005) expression was associated with early PD. AR CN status was significantly correlated with AR-V7 (p=0.05), EPCAM (p=0.02), and MDK (p=0.002) expression. In multivariable model, EPCAM and HPRT1 CTC expression, plasma AR CN gain, ECOG PS=2, and liver metastases and PSA were independently associated with poorer OS. In patients treated with cabazitaxel 20 mg/sqm, median OS was shorter in AR-V7 positive than negative patients (6.6 versus 14 months, HR=3.46, 1.47-8.17], p=0.004).
CONCLUSIONS
Baseline CTC biomarkers may be prognosticators for cabazitaxel-treated mCRPC patients. Cabazitaxel at lower (20 mg/sqm) dose was associated with poorer outcomes in AR-V7 positive patients compared to AR-V7 negative patients in a post hoc subgroup analysis.
TRIAL REGISTRATION
Clinicaltrials.gov NCT03381326 . Retrospectively registered on 18 December 2017.
Identifiants
pubmed: 35101049
doi: 10.1186/s12916-022-02244-0
pii: 10.1186/s12916-022-02244-0
pmc: PMC8805338
doi:
Substances chimiques
Biomarkers, Tumor
0
Receptors, Androgen
0
Taxoids
0
cabazitaxel
51F690397J
Banques de données
ClinicalTrials.gov
['NCT03381326']
Types de publication
Clinical Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
48Informations de copyright
© 2022. The Author(s).
Références
Eur J Cancer. 2019 Jul;116:158-168
pubmed: 31200322
Cancer Res. 2009 Jan 1;69(1):16-22
pubmed: 19117982
Clin Exp Metastasis. 2021 Apr;38(2):239-251
pubmed: 33635497
Mol Cancer Res. 2021 Jun;19(6):1040-1050
pubmed: 33771885
Int J Biochem Cell Biol. 2013 Dec;45(12):2736-48
pubmed: 24076216
J Clin Oncol. 1999 Nov;17(11):3461-7
pubmed: 10550143
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
Oncotarget. 2015 Sep 15;6(27):23358-71
pubmed: 26160840
Int J Mol Med. 2018 Feb;41(2):1147-1155
pubmed: 29207197
Sci Transl Med. 2015 Nov 4;7(312):312re10
pubmed: 26537258
Eur Urol. 2014 Jun;65(6):1198-204
pubmed: 23910941
Eur Urol. 2019 Jan;75(1):88-99
pubmed: 29673712
Clin Cancer Res. 2008 Oct 1;14(19):6302-9
pubmed: 18829513
Ann Oncol. 2015 Sep;26(9):1859-1865
pubmed: 26117829
Br J Cancer. 2009 Dec 15;101(12):1949-56
pubmed: 19888222
Oncotarget. 2018 Jun 29;9(50):29403-29413
pubmed: 30034626
Cancer Discov. 2018 Apr;8(4):444-457
pubmed: 29367197
Int J Mol Sci. 2016 Aug 11;17(8):
pubmed: 27529216
Proc Natl Acad Sci U S A. 2021 Jan 19;118(3):
pubmed: 33431674
Nat Rev Cancer. 2015 Dec;15(12):701-11
pubmed: 26563462
Crit Rev Oncol Hematol. 2021 Jan;157:103199
pubmed: 33316419
Cancer Res. 2017 Jan 1;77(1):74-85
pubmed: 27793843
Nat Commun. 2016 Nov 29;7:13668
pubmed: 27897170
J Clin Oncol. 2017 Oct 1;35(28):3198-3206
pubmed: 28809610
Cancer Res. 2012 Dec 1;72(23):6142-52
pubmed: 22971343
Adv Exp Med Biol. 2017;994:181-203
pubmed: 28560675
Nat Rev Clin Oncol. 2014 Mar;11(3):129-44
pubmed: 24445517
Expert Opin Pharmacother. 2015;16(10):1521-37
pubmed: 26067250
Oncotarget. 2016 Jul 5;7(27):41677-41690
pubmed: 27223437
Cancer Res. 2014 Apr 15;74(8):2270-2282
pubmed: 24556717
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
J Clin Oncol. 2012 Feb 20;30(6):644-6
pubmed: 22184375
N Engl J Med. 2014 Sep 11;371(11):1028-38
pubmed: 25184630
Ann Oncol. 2017 Jul 1;28(7):1508-1516
pubmed: 28472366
J Clin Oncol. 2008 Mar 1;26(7):1148-59
pubmed: 18309951
Clin Chem. 2017 Oct;63(10):1585-1593
pubmed: 28778937
Oncotarget. 2018 Nov 2;9(86):35705-35716
pubmed: 30479699
Exp Cell Res. 2021 Jun 1;403(1):112567
pubmed: 33812866
Nat Med. 1999 Mar;5(3):280-5
pubmed: 10086382
J Clin Invest. 2010 Aug;120(8):2715-30
pubmed: 20644256
JAMA Oncol. 2015 Aug;1(5):582-91
pubmed: 26181238
Eur Urol. 2019 Dec;76(6):843-851
pubmed: 31542304
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Mol Cell Oncol. 2019 Feb 26;6(2):1575691
pubmed: 31131300
Cancer Treat Rev. 2016 Feb;43:27-35
pubmed: 26827690
Eur Urol. 2015 Dec;68(6):939-45
pubmed: 26188394
Cancer Sci. 2021 Feb;112(2):859-870
pubmed: 33232539